How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Humans can recognize biological movements, such as walking, accurately and robustly. This review uses a neurophysiologically plausible and quantitative model as a tool for organizing and making sense ...

Move over karyotypes—genetic disorder detection has vastly improved. Researchers are now using array CGH (aCGH), to quickly scan through an entire genome for imbalances. Because aCGH facilitates ...

Artificial intelligence is changing the world, and simultaneously inventing a whole new language to describe how it’s doing it. Spend five minutes reading about AI and you’ll run into LLMs, RAG, RLHF, ...